NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Agios Pharmaceuticals, Inc. AGIO
15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$54.0M
▲ 48.0% vs FY2024
EPS · FY25
$-7.12
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-30.2%
Net margin · FY25
-764.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 54.0M
Revenue, FY2025 · full 15-year series below
Revenue
Net income
The company lost 764 cents on every revenue dollar this year.
Per share
USD -7.12
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-30.2%
Return on equity, FY2025
ROE
Operating margin-873.9%
Net margin-764.0%
Return on assets-27.9%
Each USD of equity lost 30 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+56.0%
−0.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years−15.7%
Change, 10 years+55.1%
The share count shrank 16% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.3B
total assets, end of FY2025
Total assetsUSD 1.3B
EquityUSD 1.2B
CashUSD 89.1M
Current ratio11.46×
Equity funds 92% of total assets.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.1
0.0
0.0
0.0
0.0
0.0
0.1
0.1
0.0
0.1
0.1
0.1
0.0
0.0
0.0
Operating income $B
−0.5
−0.4
−0.4
−0.4
−0.4
−0.3
−0.3
−0.4
−0.3
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.5
−0.4
−0.4
−0.4
−0.4
−0.3
−0.3
−0.4
−0.3
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
0.0
0.0
·
·
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
0.0
Net income $B
−0.4
0.7
−0.4
−0.2
1.6
−0.3
−0.4
−0.3
−0.3
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−7.12
11.64
−6.33
−4.23
26.55
−4.74
−6.86
−6.03
−6.75
−5.07
−3.15
−1.59
−2.83
−8.02
−8.90
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−30.2
57.3
−36.8
−19.4
189.7
−63.0
−62.0
−65.1
−85.7
−56.4
−30.6
−19.3
−132.6
·
·
Shares out B
0.06
0.06
0.06
0.06
0.05
0.07
0.07
0.06
0.05
0.04
0.04
0.04
0.03
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed